PMV Pharmaceuticals Stock Hits 52-Week Low Pmv Pharmaceuticals’ stock has fallen to a 52-week low of $1.2, reflecting a 24.24% decline over the past year. Despite the downturn, the company maintains strong liquidity with a current ratio of 12.22. Analysts suggest potential upside, with price targets ranging from $5 to $7, but challenges remain.2